GSK Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

GSK hat ein Gesamteigenkapital von £13.2B und eine Gesamtverschuldung von £17.8B, wodurch sich der Verschuldungsgrad auf 134.3% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen £58.5B bzw. £45.3B. GSK Das EBIT des Unternehmens beträgt £8.7B, so dass der Zinsdeckungsgrad 15.5 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von £4.1B.

Wichtige Informationen

134.3%

Verhältnis von Schulden zu Eigenkapital

UK£17.77b

Verschuldung

Zinsdeckungsgrad	15.5x
Bargeld	UK£4.10b
Eigenkapital	UK£13.23b
Gesamtverbindlichkeiten	UK£45.28b
Gesamtvermögen	UK£58.51b

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Apr 19

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

Jan 17

Recent updates

GSK (LON:GSK) Will Pay A Dividend Of £0.15

May 05

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: GSKDie kurzfristigen Aktiva des Unternehmens (£17.2B) decken seine kurzfristigen Passiva (£19.8B) nicht.

Langfristige Verbindlichkeiten: GSKDie kurzfristigen Vermögenswerte des Unternehmens (£17.2B) decken seine langfristigen Verbindlichkeiten (£25.4B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: GSKDie Nettoverschuldung im Verhältnis zum Eigenkapital (103.4%) wird als hoch angesehen.

Schulden abbauen: GSK Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 942.1% auf 134.3% zurückgegangen.

Schuldendeckung: GSKDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (43.2%).

Zinsdeckung: GSKDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (15.5x Coverage) gut gedeckt.

GSK Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

Recent updates

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of UK£0.16 announced

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Provides an Update on Zantac (Ranitidine) Litigation

GSK plc Provides Earnings Guidance for the Year 2024

European Medicines Agency Accepts GSK's Arexvy Filing for Adults 50-59 At Risk

Price target increased by 10% to UK£19.22

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

GSK plc to Report Q4, 2023 Results on Jan 31, 2024

GSK plc (LSE:GSK) entered into an agreement to acquire Aiolos Bio, Inc. from a group of shareholders for $1.4 billion.

Insufficient Growth At GSK plc (LON:GSK) Hampers Share Price

GSK plc Announces Positive Headline Results from Planned Analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III Trial

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Gsk plc Announces It's Jemperli (Dostarlimab) Plus Chemotherapy Approved as the First and Only Frontline Immuno-Oncology Treatment in the European Union for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK Receives Positive CHMP Opinion Recommending Momelotinib for Myelofibrosis Patients with Anaemia

Upcoming dividend of UK£0.14 per share at 4.3% yield

GSK (LON:GSK) Has Announced A Dividend Of £0.14

Gsk plc Revises Earnings Guidance for the Full Year 2023

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen